Moderna (MRNA) Is Up 151.8% After First Positive Phase 3 mRNA Cancer Therapy Result - What's Changed

Moderna (MRNA) and Merck (MRK) cancer vaccine reduced melanoma recurrence risk 49%, boosting MRNA +177% on readout. Revolution Medicines (RVMD) drug doubled pancreatic cancer survival, RVMD +163% YTD. AbbVie (ABBV) acquired Apogee for $10.9B. Barclays' Emily Field notes biotech M&A freeze is over, citing capital market reopening and oncology innovation.

Merck & Co. and Moderna Inc. reported positive results from a Phase 3 trial of their mRNA cancer vaccine, intismeran, combined with Keytruda, showing it delayed melanoma recurrence. Moderna's stock more than doubled on the news. The companies plan to share full data soon, and are testing the vaccine in other cancers. The trial marks a significant milestone for mRNA technology beyond infectious diseases.

Merck and Moderna reported on 19 August 2026 that their personalized mRNA cancer vaccine, intismeran autogene, succeeded in a Phase 3 trial for melanoma patients. The vaccine, tailored to individual tumor mutations, showed improved recurrence-free and metastasis-free survival when combined with Merck's Keytruda. Full data is pending, but initial results are statistically significant. The companies plan further trials in other cancer types.

Moderna (MRNA) stock surged 13.65% after positive Phase 3 trial results for its mRNA cancer vaccine in partnership with Merck. The trial met primary and key secondary endpoints, improving recurrence-free and distant metastasis-free survival in melanoma patients. Moderna reported Q2 revenue of $145M and a net loss of $782M, with $5.1B in cash reserves. Analysts upgraded MRNA, citing the trial's success and potential expansion into other tumor types.

Moderna and Merck reported positive late-stage trial results for an experimental mRNA-based melanoma treatment, reducing cancer recurrence. The news boosted Moderna's stock. Experts call the results remarkable, potentially opening new cancer research avenues. The treatment is personalized and combines a vaccine with Keytruda. Moderna plans to present full data at an upcoming medical meeting.

Merck and Moderna's phase 3 trial shows their experimental mRNA-based therapy, intismeran autogene, combined with Keytruda, reduced melanoma recurrence or death by 49% in stage IIB-IV patients. The treatment uses personalized mRNA vaccines to train the immune system to target cancer cells, with a 5-year follow-up showing significant risk reduction compared to Keytruda alone.